Hacking complex diseases and aging with GERO.AI

Utilizing whole-exome sequencing data for in-human AI drug discovery

Our collaborators

We Invite You to Discover Revolutionary Drugs Together

We are pioneers in AI for Drug Discovery and Aging Research fields, but we lack deep expertise in every indication. This is why we value collaboration.

If you are a Pharma or a Biotech looking for new targets with novel MoAs, do not hesitate to contact us.

Utilizing whole-exome sequencing data for in-human AI drug discovery

GERO.AI identifies rare mutations sufficiently affecting health from real-world big clinical and genetic (WES) and molecular data and then suggests druggable targets and drugs (mimicking or inhibiting) the effect of mutation to treat the disease.

We are able to aggregate the effects of multiple rare mutations on the level of biological processes and pathways and give you multiple choices of interventions with the required effect.
Our Approach

Hacking aging

Aging is a natural part and the "last mile" of a human development program, and Gero pioneer ways to understand, measure, and, ultimately, control its progression.
Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts ultimate limit of human lifespan
T. Pyrkov, K. Avchaciov, A. Tarkhov, L. Menshikov, A. Gudkov, P. Fedichev
We introduce a novel blood-based biomarker of aging, the dynamic organism state indicator (DOSI). DOSI is associated with frailty and predicts the prospective incidence of age-related diseases and death. Age-related broadening of DOSI distribution is associated with a progressive loss of physiological resilience. Extrapolation suggests that recovery time would diverge at a critical point of 120 – 150 years of age and signifies a fundamental or absolute limit of human lifespan.
Gero in media